

CV Date	15/05/2023
---------	------------

Part A. PERSONAL INFORMATION

First Name	Javier		
Family Name	De Las Rivas Sanz		
Sex	Not Specified	Date of Birth	
ID number Social Security, Passport			
URL Web	http://bioinfow.dep.usal.es/		
Email Address	jrivas@usal.es		
Open Researcher and Contributor ID (ORCID)	0000-0002-0984-9946		

A.1. Current position

Job Title	Investigador Científico CSIC (2006) (Científico Titular en 1998)		
Starting date	1998		
Institution	Consejo Superior de Investigaciones Científicas		
Department / Centre	Translational and Clinical Research in Cancer / Centro de Investigación del Cáncer (CiC-IBMCC, CSIC/USAL)		
Country	Spain	Phone Number	(34) 923294819
Keywords	Biomedicine; Computational biology; Genomics		

A.2. Previous positions (Research Career breaks included)

Period	Job Title / Name of Employer / Country
2002 - 2006	Científico Titular / CiC-IBMCC, CSIC/USAL (Salamanca)
1998 - 2002	Científico Titular / IRNA, CSIC (Salamanca)
2000 - 2001	Visiting Professor / Mount Sinai School Medicine (NY, USA)
1995 - 1998	Profesor Titular Interino (Facultad de Ciencias) / Universidad del País Vasco UPV/EHU (Bilbao)
1994 - 1994	Profesor Asociado (Facultad de Ciencias) / Univ. País Vasco UPV/EHU (Bilbao)
1992 - 1993	Research Fellow FEBS / Imperial College (London, UK)
1990 - 1992	Becario Postdoctoral FPI-MEC / Imperial College (London, UK)

A.3. Education

Degree/Master/PhD	University / Country	Year
Doctor en Bioquímica y Biología Molecular	Universidad del País Vasco	1990
Licenciado C. Biológicas Grado (por Tesina)	Universidad del País Vasco	1985
Licenciado en Ciencias Biológicas	Universidad del País Vasco	1984

Part B. CV SUMMARY

— — — DIRECTOR / SUPERVISOR of **16 DOCTORAL THESIS, PhDs** (5 recent) — — —:

- TITLE: **Bioinformatic analysis and deep learning on large-scale human transcriptomic data: studies on aging, Alzheimer's neurodegeneration and cancer.** DOCTOR: **Óscar González Velasco.** University of Salamanca. DATE & QUALIFICATION: 2.Jun.2021 Sobresaliente Cum Laude *Mención INTERNACIONAL.
- TITLE: **Preclinical evaluation of BH3-mimetics targeting MCL-1 and BCL-2 in Multiple Myeloma.** DOCTOR: **Macarena Algarín Pachón.** University of Salamanca. DATE & QUALIF.: 22.Jul.2020 Sobresaliente Cum Laude *Mención INTERNACIONAL.
- TITLE: **Development & application of bioinformatic methods to analyze genome-wide expression and survival data of cancer patients.** DOCTOR: **Santiago Bueno Fortes.** University of Salamanca. DATE & QUALIF.: 5.Sep.2019 Sobresaliente Cum Laude.

- TITLE: **Bioinformatics applied to human genomics and proteomics: development of algorithms & methods for the discovery of molecular signatures derived from omic data.** DOCTOR: **Francisco J. Campos Laborie.** University of Salamanca. DATE & QUALIFICATION: 14.Sep.2018 Sobresaliente Cum Laude *Mención INTERNACIONAL.
- TITLE: **Bioinformatics to integrate protein and gene information in a relational context, application to human proteomic and transcriptomic data.** DOCTOR: **Conrad Friedrich Droste.** University of Salamanca. DATE & QUALIFICATION: 4.Sep.2017 Sobresaliente Cum Laude.
- — — BRIEF SUMMARY OF OTHER DATA, SOME ALREADY REPORTED — — —:
- Accreditation with: **5 SEXENIOS:** (1986-91, 1992-98, 1999-04, 2005-10, 2011-16) y **7 QUINQUENIOS:** (1986-90, 1991-95, 1996-00, 2001-05, 2006-10, 2011-15, 2016-20).
- **RESEARCH PROJECTS: 49. PUBLICATIONS: 207 = 167** Articles in International Scientific Journals (JCR). **3** Articles in Popular Scientific Magazines. **4** Articles in Scientific Journals not included in JCR. Books: Edited Book **1**; Chapters in Books **9**; Book Chapter Translation (Stryer Biochemistry) **1**; Articles in Scientific Monographs (with ISBN) **23**.
- **Cumulative Impact Factor (CIF) > 1100** (in January 2023), with an **h-index** (Hirsch index) = **55** (by "Google Scholar") and = **44** (by "Scopus")..
- Vice-Chair of **European COST ACTION CA17104: STRATAGEN, New diagnostic and therapeutic tools against multidrug resistant tumors** (**4 years**, Sep.2018-Sep.2022: www.cost.eu/actions/CA17104/).
- Member of **European COST ACTION CA17118: TRANSCOLONCAN, Identifying biomarkers through translational research for prevention & stratification of Colorectal Cancer** (**4 years**, Oct.2018-Oct.2022: www.cost.eu/actions/CA17118/).
- To see **global Scientific-Researcher career, quality & international impact of scientific publications:** <http://scholar.google.com/citations?hl=en&user=VY2k-EQAAAAJ> OR <https://www.ncbi.nlm.nih.gov/pubmed/?term=De+Las+Rivas+J+OR+Rivas+Jde+L>

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 Scientific paper.** Landeira-Viñuela A; ...; De Las Rivas J. (13/16). 2023. "Systematic evaluation of antigenic stimulation in Chronic Lymphocytic Leukemia: humoral immunity as biomarkers for disease evolution". *Cancers* (2023) 15(3):891. PMID:36765855 [IF:6.639/Q1]. ISSN 2072-6694. <https://doi.org/10.3390/cancers15030891>
- 2 Scientific paper.** García-Vaquero ML; Gama-Carvalho M; Pinto FR; De Las Rivas J (AC). (4/4). 2022. "Biological interacting units identified in human protein networks reveal tissue-functional diversification and its impact on disease". *Comput Struct Biotechnol J.* (2022) 20:3764-78. PMID:35891788 [IF:6.155/Q1]. ISSN 2001-0370. <https://doi.org/10.1016/j.csbj.2022.07.006>
- 3 Scientific paper.** Bueno-Fortes S; ...; De Las Rivas J. (13/14). 2021. "A gene signature derived from the loss of CDKN1A (p21) is associated with CMS4 colorectal cancer". *Cancers* (2021) 14(1):136. PMID:35008299 [IF:6.639/Q1]. ISSN 2072-6694. <https://doi.org/10.3390/cancers14010136>
- 4 Scientific paper.** Herrera M; ...; De Las Rivas J. (13/13). 2021. "Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients". *Molecular Cancer* (2021) 20(1):73. PMID:33926453 [IF:41.444 / D1]. ISSN 1476-4598. <https://doi.org/10.1186/s12943-021-01367-x>
- 5 Scientific paper.** Raboso-Gallego J; ...; De Las Rivas J. (11/15). 2021. "Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice". *Blood* (2021) 137(13):1741-1753. PMID:33024996 [IF:23.629/D1]. ISSN 0006-4971. <https://doi.org/10.1182/blood.2020004996>

- 6 **Scientific paper.** Luck K; ...2020. "A reference map of the human binary protein interactome". *NATURE* (2020) 580:402. PMID:32296183 [IF:49.962/D1].ISSN 1476-4687. <https://doi.org/10.1038/s41586-020-2188-x>
- 7 **Scientific paper.** Vicente Dueñas C; ...; De Las Rivas J. (14/23). 2020. "An intact gut microbiome protects genetically predisposed mice against leukemia". *Blood* (2020) 136(18):2003-2017. PMID: 32911536 [IF:23.629/D1]. ISSN 0006-4971. <https://doi.org/10.1182/blood.2019004381>
- 8 **Scientific paper.** Cortes-Urrea C; Bueno-Gutiérrez F; Solarte M; et al; De Las Rivas J (AC). (11/11). 2020. "Exomes of Ductal Luminal Breast Cancer patients from Southwest Colombia: gene mutational profile and related expression alterations". *Biomolecules* (2020) 10:698. PMID:32365829 [IF:4.082/Q2].ISSN 2218-273X. <https://doi.org/10.3390/biom10050698>
- 9 **Scientific paper.** Blanco-Gomez A; ...; De Las Rivas J. (10/23). 2020. "Stromal SNAI2 is required for ERBB2 breast cancer progression". *Cancer Research* (2020) 80:5216. PMID:33023950 [IF:12.701/D1]. ISSN 0008-5472. <https://doi.org/10.1158/0008-5472.CAN-20-0278>
- 10 **Scientific paper.** Corchete LA; Rojas EA; Alonso-López D; De Las Rivas J (AC); Gutiérrez NC; Burguillo FJ. (4/6). 2020. "Systematic comparison and assessment of RNA-seq procedures for gene expression quantitative analysis". *Scientific Reports* (2020) 10:19737. PMID:33184454 [IF:3.998/Q1].ISSN 2045-2322. <https://doi.org/10.1038/s41598-020-76881-x>
- 11 **Scientific paper.** González-Velasco O; Papy-García D; Le Douaron G; Sánchez-Santos JM; De Las Rivas J (AC). (5/5). 2020. "Transcriptomic landscape, gene signatures and regulatory profile of aging in the human brain". *BBA Gene Regul Mech* (2020) 1863:194491. PMID:32006715 [IF:3.510/Q1].ISSN 1874-9399. <https://doi.org/10.1016/j.bbagr.2020.194491>
- 12 **Scientific paper.** Alonso-López D; Campos-Laborie FJ; Gutiérrez MA; Lambourne L; Calderwood MA; Vidal M; De Las Rivas J (AC). (7/7). 2019. "APID database: redefining protein-protein interaction experimental evidences and binary interactomes". *Database* (2019) 2019:baz005. PMID:30715274 [IF:2.593/Q1].ISSN 1758-0463. <https://doi.org/10.1093/database/baz005>
- 13 **Scientific paper.** De Las Rivas J (AC); Bonavides-Martínez C; Campos-Laborie FJ. (1/3). 2019. "Bioinformatics in Latin America and SolBio impact, a tale of spin-off and expansion around genomes and protein structures". *Brief Bioinform* (2019) 20:390. PMID:28981567 [IF:8.990/D1].ISSN 1467-5463. <https://doi.org/10.1093/bib/bbx064>
- 14 **Scientific paper.** Campos-Laborie FJ; Risueño A; Ortiz-Estévez M; et al; De Las Rivas J (AC). (10/10). 2019. "DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling". *Bioinformatics* (2019) 35:3651. PMID:30824909 [IF:5.610/D1].ISSN 1367-4803. <https://doi.org/10.1093/bioinformatics/btz148>
- 15 **Scientific paper.** Choi SG; ... (19/26). 2019. "Maximizing binary interactome mapping with a minimal number of assays". *Nature Commun.* (2019) 10:3907. PMID:31467278 [IF:11.878/D1].ISSN 2041-1723. <https://doi.org/10.1038/s41467-019-11809-2>
- 16 **Review.** Alves R; ...; De Las Rivas J. (5/7). 2021. "Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia - from molecular mechanisms to clinical relevance". *Cancers* (2021) 13(19):4820. PMID:34638304 [IF:6.639/Q1]. ISSN 2072-6694. <https://doi.org/10.3390/cancers13194820>
- 17 **Review.** Perez-Ruiz E; Melero I; Kopecka J; Sarmiento-Ribeiro AB; Garcia-Aranda M; De Las Rivas J (AC). (6/6). 2020. "Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies". *Drug Resist Updat.* (2020) 53:100718. PMID:32736034 [IF:18.500/D1].ISSN 1368-7646. <https://doi.org/10.1016/j.drup.2020.100718>
- 18 **Scientific paper.** Landeira-Viñuela A; et al.(13/16). 2022. "Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction". *Front Immunol.* (2022) 13:965905. PMID:36248816 [IF:8.787/Q1]. ISSN 1664-3224. <https://doi.org/10.3389/fimmu.2022.965905>

- 19 Scientific paper.** Casado-García A; et al.(15/28). 2022. "Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice". *Cancer Res.* (2022) canres.3386.2021. PMID:35131871 [IF:13.312/D1]. ISSN 0008-5472. <https://doi.org/10.1158/0008-5472.CAN-21-3386>
- 20 Review.** Kopecka J; ...; De Las Rivas J. (6/7). 2021. "Hypoxia as a driver of resistance to immunotherapy". *Drug Resist Updat.* (2021) 59:100787. PMID:34840068 [IF:18.500/D1]. ISSN 1368-7646. <https://doi.org/10.1016/j.drug.2021.100787>

C.3. Research projects and contracts

- 1 Project.** "Análisis proteo-transcriptómico por técnicas de célula única del microambiente inmune y estromal de la médula ósea para descifrar la respuesta a tratamiento en mieloma múltiple". Ministerio de Sanidad y Consumo ISCIII – AES 2022 (ref: PI18/00591). (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 01/01/2023-31/12/2025. 171.820 €.
- 2 Project.** "IMPACT-Data. Programa Ciencia de Datos". Ministerio de Ciencia e Innovación - ISCIII y FEDER (ref. IMP/00019). (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 01/01/2021-31/12/2023. 112.250,05 €.
- 3 Project.** "Onco-proteogenómica personalizada aplicada a hemopatías malignas e inmuno-modulación: desarrollo de métodos bioinformáticos para búsqueda de marcadores ... en pacientes y donantes". Ministerio de Sanidad y Consumo ISCIII – AES 2018 (ref: PI18/00591). (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 01/01/2019-30/06/2023. 99.220 €.
- 4 Project.** "ArrestAD: 3-O-sulfated heparan sulfate translocation in altered membrane biology: A new strategy for early population screening and halting Alzheimer's neurodegeneration". EU programa Horizon 2020, H2020-FETOPEN-2016-2017 (referencia de proyecto: 737390). (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 01/01/2017-31/05/2022. 452.375 €.
- 5 Project.** "Fly-SMALS: Common RNA-dependent pathways for motor neuron degeneration in spinocerebellar muscular atrophy and amyotrophic lateral sclerosis". EU Joint Programme - Neurodegenerative Disease Research (ref. JPND_CD_FP-688-085); Ministerio de Sanidad y Consumo ISCIII (referencia de proyecto: AC14/00024 y JPND_CD_FP-688-085). (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 31/05/2015-30/06/2019. 49.610 €.
- 6 Project.** "Identificación y validación de activadores Ras-GEF de las familias Sos y Grf como biomarcadores y dianas terapéuticas en procesos fisiológicos y tumorales mediante el uso de animales modelo y aproximaciones preclínicas". Junta de Castilla y León, Consejería de Educación y Fondos FEDER (referencia de proyecto: SA043U16). (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 01/06/2016-31/05/2019. 120.000 €.
- 7 Project.** "Genómica y proteómica integrativa de hemopatías malignas mieloides y mieloma múltiple: estudio bioinformático de datos ómicos de muestras clínicas para identificar marcadores de pronóstico, respuesta y supervivencia, y estratificación eficaz de pacientes". Ministerio de Sanidad y Consumo ISCIII – AES 2015 (referencia de proyecto: PI15/00328). (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 01/01/2016-31/12/2018. 62.315 €.
- 8 Project.** "Transcriptómica y epigenómica de Células Stem Mesenquimales (MSC) normales y alteradas en hemopatías malignas". Junta de Castilla y León - Consejería Sanidad (referencia de proyecto: BIO/SA68/13). (Instituto de Biología Molecular y Celular del Cáncer de Salamanca). 15/11/2013-15/11/2014. 23.500 €.

C.4. Activities of technology / knowledge transfer and results exploitation

- 1 EP21383041.** "In vitro method for the identification of human Mesenchymal Stem/Stromal Cells". Spain. 17/11/2021. Instituto de Investigación Biomédica de Salamanca (IBSAL-IIS), Salamanca.
- 2 2006/0234.** "Modelos experimentales para la METÁSTASIS a hueso del CÁNCER DE PULMON no microcítico". Spain. 15/09/2006. Centro de Investigación Médica Aplicada (CIMA, FIMA, Pamplona, Navarra).